Merck Declares $0.85 Per-Share Q3 Dividend, Backed by Keytruda Momentum

Merck & Co. declared a quarterly dividend of $0.85 per share for Q3 2026, payable on July 8, 2026, to shareholders of record as of June 15, 2026. At recent prices, the dividend implies a yield of approximately 2.82%, a signal from the board that the company's cash generation remains solid. The announcement arrives as Merck continues to ride Keytruda's commercial momentum, with the immunotherapy treatment serving as the cornerstone of the company's revenue base.

Merck's payout story rests heavily on Keytruda, which has become one of the best-selling pharmaceuticals globally. The European Medicines Agency recently issued a positive opinion for an expanded Keytruda indication in combination with Padcev for certain bladder cancer patients, a move that could further extend the franchise's addressable market. Revenue growth from Keytruda has provided the cash flow that underpins Merck's consistent dividend payments.

The risks to this story are structural. Keytruda's core patents face expiration in the late 2020s, and while Merck has pursued pipeline diversification and co-formulation strategies to extend the franchise, biosimilar competition is a long-term pressure that investors may weigh against the current dividend story. In the near term, the steady Q3 2026 payout could appeal to income-oriented investors, but its longer-run sustainability ultimately depends on whether the pipeline delivers meaningful new revenue before Keytruda's exclusivity window closes.

Related Stocks

• MRK